ReviewFrontiers in pharmacology2020
A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 3 syntheses or guidelines pooled it, 213 citations in OpenAlex.
- Facilitating the use of the target product profile in academic research: a systematic review.Journal of translational medicine · 2024Pooled it
- Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.Human vaccines & immunotherapeutics · 2022Pooled it
- Pooled it
- Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects.Scientific reports · 2024Article
- Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada.BMC infectious diseases · 2024Article
- Type I interferon pathway genetic variants in severe COVID-19.Virus research · 2024Review
- SARS-CoV-2 genetic variation and bacterial communities of naso-oropharyngeal samples in middle-aged and elderly COVID-19 patients in West Java, Indonesia.Journal of Taibah University Medical Sciences · 2024Article
- Why should I vaccinate? The role of mindfulness and health-protective behaviours during the COVID-19 pandemic.Health policy and technology · 2023Article
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
- Development of SARS-CoV-2 Vaccine: Challenges and Prospects.Diseases (Basel, Switzerland) · 2023Review
- A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?Vaccines · 2023Article
- Article
- Minimizing Viral Transmission in COVID-19 Like Pandemics: Technologies, Challenges, and Opportunities.IEEE sensors journal · 2023Article
- Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19.Plasmonics (Norwell, Mass.) · 2023Review
- Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.Human vaccines & immunotherapeutics · 2022Article
- Coronavirus disease 2019 (COVID-19) vaccines: A concise review.Oral diseases · 2022Review
- Article
- Review
- Article
- COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.Clinics in geriatric medicine · 2022Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has entered the human population and has spread rapidly around the world in the first half of 2020 causing a global pandemic. The virus uses its spike glycoprotein receptor-binding domain to interact with host cell angiotensin-converting enzyme 2 (ACE2) sites to initiate a cascade of events that culminate in severe acute respiratory syndrome in some individuals. In efforts to curtail viral spread, authorities initiated far-reaching lockdowns that have disrupted global economies. The scientific and medical communities are mounting serious efforts to limit this pandemic and subsequent waves of viral spread by developing preventative vaccines and repurposing existing drugs as potential therapies. In this review, we focus on the latest developments in COVID-19 vaccine development, including results of the first Phase I clinical trials and describe a number of the early candidates that are emerging in the field. We seek to provide a balanced coverage of the seven main platforms used in vaccine development that will lead to a desired target product profile for the "ideal" vaccine. Using tales of past vaccine discovery efforts that have taken many years or that have failed, we temper over exuberant enthusiasm with cautious optimism that the global medical community will reach the elusive target to treat COVID-19 and end the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.